Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp Further Extends Offer for Orchid Cellmark

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Laboratory Corporation of America has extended its tender offer to acquire all of the outstanding shares of Orchid Cellmark until 5:00 p.m., New York City time, on July 15, 2011.

The offer had been scheduled to expire on June 15. Last month, LabCorp received a request from the US Federal Trade Commission seeking additional information for its review of the $85.4 million acquisition.

LabCorp said today that it is cooperating with the FTC and as a consequence has extended the offer period. It said that as of 6:00 p.m. last night, Orchid shareholders had tendered around 26.5 million shares of common stock representing roughly 88 percent of the firm's outstanding stock.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.